Genomic DNA (gDNA) (gDNA)

Genomic DNA (gDNA) within neuronal and cortical cells serves as the comprehensive blueprint for the development, maintenance, and functional plasticity of the central nervous system (Alberts et al., 2014). Because neurons are primarily post-mitotic, the integrity of their genomic DNA is critical; the accumulation of DNA damage or the failure of repair mechanisms is a hallmark of aging and neurodegenerative diseases such as Alzheimer's and Parkinson's (Madabhushi et al., 2014, Neuron). In oncology, genomic DNA in cortical cells is a primary target for alkylating agents like temozolomide, which induce DNA damage to trigger apoptosis in malignant glioma cells (PubChem, CID 5394). Modern therapeutic strategies are shifting toward precision modification of genomic DNA using gene therapies and CRISPR-based systems to correct pathogenic mutations or provide functional gene copies in disorders like spinal muscular atrophy (NIH, 2023). However, the therapeutic manipulation of genomic DNA presents significant challenges, including the risk of off-target effects, permanent genotoxicity, and the potential for inducing secondary cancers (FDA, 2022; StatPearls, 2023).

Other names

Nuclear DNAChromosomal DNAGenomeTotal cellular DNA

Agents targeting genomic DNA operate through several mechanisms: alkylating agents (e.g., temozolomide) add alkyl groups to DNA, causing cross-links or strand breaks that trigger apoptosis; intercalating agents (e.g., doxorubicin) wedge between base pairs to inhibit topoisomerases; and gene therapies (e.g., onasemnogene abeparvovec) deliver functional genetic material to the nucleus to compensate for defective endogenous DNA (PubChem CID 5394; NIH, 2023).